Perspective Therapeutics (CATX) Other Non-Current Liabilities (2011 - 2026)
Perspective Therapeutics recorded quarterly Other Non-Current Liabilities of $437000.0 in Q1 2026, up 13.21% quarter-over-quarter from $386000.0 in Q4 2025, and up 201.38% year-over-year from $145000.0 in Q1 2025.
Perspective Therapeutics' Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $437000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 201.38% year-over-year to $437000.0; the TTM figure through Mar 2026 stood at $437000.0 (up 201.38% YoY), while the FY2025 annual figure was $386000.0, up 601.82% from the prior year.
- Other Non-Current Liabilities came in at $437000.0 for Q1 2026 at Perspective Therapeutics, up from $386000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $668000.0 in Q3 2023 to a low of $19000.0 in Q2 2024.
- A 5-year average of $418133.3 and a median of $437000.0 in 2026 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities slumped 97.12% in 2024 and soared 1394.74% in 2025, its largest moves.
- Perspective Therapeutics' Other Non-Current Liabilities stood at $657000.0 in 2022, then gained by 1.67% to $668000.0 in 2023, then plunged by 91.77% to $55000.0 in 2024, then soared by 601.82% to $386000.0 in 2025, then climbed by 13.21% to $437000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $437000.0, $386000.0, and $342000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Perspective Therapeutics | 380.23 Mn | 380.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 437,000.00 |
| Dec 31, 2025 | 386,000.00 |
| Sep 30, 2025 | 342,000.00 |
| Jun 30, 2025 | 284,000.00 |
| Mar 31, 2025 | 145,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Sep 30, 2023 | 668,000.00 |
| Jun 30, 2023 | 659,000.00 |
| Mar 31, 2023 | 666,000.00 |
| Dec 31, 2022 | 657,000.00 |
| Sep 30, 2022 | 649,000.00 |
| Jun 30, 2022 | 640,000.00 |
| Mar 31, 2022 | 632,000.00 |
| Dec 31, 2021 | 624,000.00 |
| Sep 30, 2021 | 616,000.00 |
| Jun 30, 2021 | 608,000.00 |
| Mar 31, 2021 | 600,000.00 |
| Dec 31, 2020 | 593,000.00 |
| Sep 30, 2020 | 585,000.00 |
| Jun 30, 2020 | 577,000.00 |
| Mar 31, 2020 | 570,000.00 |
| Dec 31, 2019 | 563,000.00 |
| Sep 30, 2019 | 555,000.00 |
| Jun 30, 2019 | 621,000.00 |
| Mar 31, 2019 | 613,000.00 |
| Dec 31, 2018 | 606,000.00 |
| Sep 30, 2018 | 598,000.00 |
| Jun 30, 2018 | 590,000.00 |
| Mar 31, 2018 | 583,000.00 |
| Dec 31, 2017 | 576,000.00 |
| Sep 30, 2017 | 568,000.00 |
| Jun 30, 2017 | 561,000.00 |
| Mar 31, 2017 | 554,000.00 |
| Dec 31, 2016 | 547,000.00 |
| Jun 30, 2016 | 580,000.00 |
| Mar 31, 2016 | 1.01 Mn |
| Dec 31, 2015 | 991,000.00 |
| Jun 30, 2015 | 947,000.00 |
| Jun 30, 2014 | 866,560.00 |
| Mar 31, 2014 | 678,000.00 |
| Dec 31, 2013 | 23,000.00 |
| Sep 30, 2013 | 810,202.00 |
| Jun 30, 2013 | 792,242.00 |
| Mar 31, 2013 | 131,000.00 |
| Dec 31, 2012 | 757,509.00 |
| Sep 30, 2012 | 740,717.00 |
| Jun 30, 2012 | 724,298.00 |
| Mar 31, 2012 | 708,243.00 |
| Dec 31, 2011 | 692,543.00 |
| Sep 30, 2011 | 677,192.00 |
| Jun 30, 2011 | 662,181.00 |